Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy-Reference-Cited by-同舟云学术

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Published:2018-02-02 Issue:6375 Volume:359 Page:582-587
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Chowell Diego¹²,Morris Luc G. T.²³^ORCID,Grigg Claud M.⁴^ORCID,Weber Jeffrey K.⁵,Samstein Robert M.¹²^ORCID,Makarov Vladimir¹²^ORCID,Kuo Fengshen¹²^ORCID,Kendall Sviatoslav M.¹²^ORCID,Requena David⁶^ORCID,Riaz Nadeem¹²⁷,Greenbaum Benjamin⁸,Carroll James⁹^ORCID,Garon Edward⁹,Hyman David M.¹⁰¹¹^ORCID,Zehir Ahmet¹²^ORCID,Solit David¹¹⁰¹³^ORCID,Berger Michael¹¹²¹³^ORCID,Zhou Ruhong⁵¹⁴^ORCID,Rizvi Naiyer A.⁴^ORCID,Chan Timothy A.¹²⁷¹¹^ORCID

Affiliation:

1. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

2. Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

4. NewYork-Presbyterian/Columbia University Medical Center, 177 Fort Washington Avenue, New York, NY 10032, USA.

5. IBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598, USA.

6. Laboratory of Cellular Biophysics, The Rockefeller University, New York, NY 10065, USA.

7. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

8. Tisch Cancer Institute, Departments of Medicine, Oncological Sciences, and Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

9. David Geffen School of Medicine, University of California, Los Angeles, 2825 Santa Monica Boulevard, Suite 200, Santa Monica, CA 90404, USA.

10. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

11. Weill Cornell School of Medicine, New York, NY 10065, USA.

12. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

13. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

14. Department of Chemistry, Columbia University, New York, NY 10027, USA.

Abstract

HLA genotype affects response Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516

Funder

Damon Runyon Cancer Research Foundation

NIH

Starr Cancer Consortium

Pershing Square Sohn Cancer Research Alliance

NIH/NCI Cancer Center Support Grant

Stand Up 2 Cancer

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference86 articles.